Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
View abstract on PubMed
Summary
This summary is machine-generated.Metastatic renal-cell carcinoma patients with indolent disease can safely undergo active surveillance. This approach delays systemic therapy initiation, with a median surveillance time of 14.9 months in a phase 2 trial.
Area Of Science
- Oncology
- Clinical Trials
Background
- Metastatic renal-cell carcinoma (mRCC) can exhibit indolent growth.
- Systemic therapy for mRCC has toxicity and is non-curative.
- Active surveillance may benefit selected mRCC patients.
Purpose Of The Study
- To characterize the time to initiation of systemic therapy in mRCC patients under active surveillance.
- To evaluate the safety and feasibility of active surveillance in treatment-naive, asymptomatic mRCC patients.
Main Methods
- Prospective phase 2 trial enrolling treatment-naive, asymptomatic mRCC patients.
- Radiographic assessments every 3-6 months.
- Primary endpoint: time to initiation of systemic therapy.
Main Results
- Median follow-up was 38.1 months.
- Median time on surveillance until systemic therapy initiation was 14.9 months (n=48).
- Higher IMDC adverse risk factors and more metastatic sites correlated with shorter surveillance.
Conclusions
- Active surveillance is a safe option for a subset of mRCC patients before systemic therapy.
- Further research is needed to define the benefits and risks of this strategy.